keyword
MENU ▼
Read by QxMD icon Read
search

Asbergers

keyword
https://www.readbyqxmd.com/read/28906325/antidepressant-combination-versus-antidepressants-plus-second-generation-antipsychotic-augmentation-in-treatment-resistant-unipolar-depression
#1
Gabriella Gobbi, Maykel F Ghabrash, Nicolas Nuñez, John Tabaka, Jessica Di Sante, Marie Saint-Laurent, Stephen Vida, Theodore Kolivakis, Nancy Low, Pablo Cervantes, Linda Booij, Stefano Comai
Patients with treatment-resistant unipolar depression (TRD) are treated with antidepressant combinations (ADs) or with second-generation antipsychotics plus AD (SGA+AD) augmentation; however, the clinical characteristics, the factors associated independently with response to SGA+AD, and the outcome trajectories have not yet been characterized. We performed a naturalistic study on the latest stable trial (medication unchanged for about 3 months) in 86 TRD patients with resistance to at least two ADs trials, who received ADs (n=36) or SGA+AD (n=50) treatments...
September 12, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28892734/acute-change-in-anterior-cingulate-cortex-gaba-but-not-glutamine-glutamate-mediates-antidepressant-response-to-citalopram
#2
Brian P Brennan, Roee Admon, Chris Perriello, Erin M LaFlamme, Alison J Athey, Diego A Pizzagalli, James I Hudson, Harrison G Pope, J Eric Jensen
Little is known about the acute effects of antidepressant treatments on brain glutamate and gamma-amino-butyric acid (GABA) levels, and their association with clinical response. Using proton magnetic resonance spectroscopy ((1)H-MRS) we examined longitudinally the effects of citalopram on glutamine/glutamate ratios and GABA levels in the pregenual anterior cingulate cortex (pgACC) of individuals with major depressive disorder (MDD). We acquired (1)H-MRS scans at baseline and at days 3, 7, and 42 of citalopram treatment in nineteen unmedicated individuals with MDD...
September 1, 2017: Psychiatry Research
https://www.readbyqxmd.com/read/28882405/efficacy-of-quetiapine-xr-vs-placebo-as-concomitant-treatment-to-mood-stabilizers-in-the-control-of-subthreshold-symptoms-of-bipolar-disorder-results-from-a-pilot-randomized-controlled-trial
#3
Marina Garriga, Eva Solé, Ana González-Pinto, Gabriel Selva-Vera, Belén Arranz, Benedikt L Amann, Jerónimo Saiz-Ruiz, Josefina Pérez-Blanco, Eduard Vieta
Patients with bipolar disorder (BD) do not always achieve full remission between episodes. Subthreshold symptoms (depressive, manic or mixed) represent a major cause of relapse and disability in these patients. Immediate release (IR) and extended release (XR) formulations of quetiapine are both indicated for short and long-term treatment of BD. The aim of this study was to evaluate the efficacy of quetiapine XR vs placebo in subthreshold symptomatology when added to previous mood stabilizer treatment. A pilot phase IIIB, multicentre, prospective, placebo controlled, randomized, double blinded study of 12 weeks follow-up was performed (NCT01197846)...
September 4, 2017: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28881454/hypersensitivity-to-low-intensity-fearful-faces-in-autism-when-fixation-is-constrained-to-the-eyes
#4
Amandine Lassalle, Jakob Åsberg Johnels, Nicole R Zürcher, Loyse Hippolyte, Eva Billstedt, Noreen Ward, Eric Lemonnier, Christopher Gillberg, Nouchine Hadjikhani
Previous studies that showed decreased brain activation in people with autism spectrum disorder (ASD) viewing expressive faces did not control that participants looked in the eyes. This is problematic because ASD is characterized by abnormal attention to the eyes. Here, we collected fMRI data from 48 participants (27 ASD) viewing pictures of neutral faces and faces expressing anger, happiness, and fear at low and high intensity, with a fixation cross between the eyes. Group differences in whole brain activity were examined for expressive faces at high and low intensity versus neutral faces...
September 7, 2017: Human Brain Mapping
https://www.readbyqxmd.com/read/28865389/self-assessed-remission-rates-after-electroconvulsive-therapy-of-depressive-disorders
#5
O Brus, Y Cao, E Gustafsson, M Hultén, M Landen, J Lundberg, P Nordanskog, A Nordenskjöld
BACKGROUND: Electroconvulsive therapy (ECT) effectively treats severe depression, but not all patients remit. The aim of the study was to identify clinical factors that associate with ECT-induced remission in a community setting. METHODS: Depressed patients who underwent ECT in 2011-2014 were identified from the Swedish National Quality Register for ECT. Remission was defined as self-rated Montgomery-Åsberg Depression Rating Scale scores of 0-10 after ECT. Other registers provided data on previous antidepressant use, comorbidities, and demographics...
July 21, 2017: European Psychiatry: the Journal of the Association of European Psychiatrists
https://www.readbyqxmd.com/read/28858659/are-self-report-scales-as-effective-as-clinician-rating-scales-in-measuring-treatment-response-in-routine-clinical-practice
#6
Mark Zimmerman, Emily Walsh, Michael Friedman, Daniela A Boerescu, Naureen Attiullah
OBJECTIVE: Recent treatment guidelines have suggested that outcome should be measured in routine clinical practice. In the present report from the Rhode Island Methods to Improve Diagnostic Assessment and Services (MIDAS) project, we compared three self-report scales of depressive symptoms and the two most widely used clinician administered scales in treatment studies in their sensitivity to change and evaluation of treatment response in depressed patients treated in routine practice...
August 15, 2017: Journal of Affective Disorders
https://www.readbyqxmd.com/read/28858412/a-randomized-double-blind-placebo-controlled-8-week-trial-of-the-efficacy-safety-and-tolerability-of-5-10-and-20-mg-day-vortioxetine-in-adults-with-major-depressive-disorder
#7
Akira Nishimura, Yutaka Aritomi, Kiyofumi Sasai, Tadayuki Kitagawa, Atul R Mahableshwarkar
AIM: This study assessed the efficacy and safety of vortioxetine in adults with major depressive disorder. METHODS: In this double-blind, placebo-controlled study, 600 patients with major depressive disorder were randomly assigned (1:1:1:1) to receive vortioxetine 5, 10, or 20 mg, or placebo once daily for 8 weeks. The primary endpoint was change from baseline in Montgomery-Åsberg Depression Rating Scale total score at week 8, evaluated by the last observation carried forward method...
August 31, 2017: Psychiatry and Clinical Neurosciences
https://www.readbyqxmd.com/read/28857719/a-randomized-double-blind-placebo-controlled-dose-ranging-study-of-lisdexamfetamine-dimesylate-augmentation-for-major-depressive-disorder-in-adults-with-inadequate-response-to-antidepressant-therapy
#8
Cynthia Richards, Dan V Iosifescu, Rajnish Mago, Elias Sarkis, James Reynolds, Brooke Geibel, Matthew Dauphin
BACKGROUND: This randomized, double-blind, placebo-controlled study evaluated dose-response relationships of lisdexamfetamine dimesylate when used as augmentation for major depressive disorder in individuals exhibiting inadequate responses to antidepressant monotherapy. METHODS: Eligible adults (18-65 years) were assigned to antidepressant monotherapy (escitalopram or venlafaxine extended-release) plus lisdexamfetamine dimesylate-matching placebo during an eight-week single-blind lead-in phase...
August 1, 2017: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/28839341/long-term-safety-and-tolerability-of-valbenazine-nbi-98854-in-subjects-with-tardive-dyskinesia-and-a-diagnosis-of-schizophrenia-or-mood-disorder
#9
Richard C Josiassen, John M Kane, Grace S Liang, Joshua Burke, Christopher F O'Brien
BACKGROUND: The short-term safety profile of once-daily valbenazine (NBI-98854) has been evaluated in several double-blind, placebo-controlled (DBPC) trials in adults with tardive dyskinesia (TD) who had a diagnosis of schizophrenia/schizoaffective (SCHZ) disorder or mood disorder. Studies with longer treatment duration (up to 48 weeks) were conducted to evaluate the long-term safety of this novel drug in subjects with TD. METHODS: The pooled long-term exposure (LTE) population included valbenazine-treated subjects from 3 studies: KINECT (NCT01688037: 6-week DBPC, 6-week open-label); KINECT 3 (NCT02274558: 6-week DBPC, 42-week blinded extension, 4-week drug-free follow-up); KINECT 4 (NCT02405091: 48-week open-label, 4-week drug-free follow-up)...
August 1, 2017: Psychopharmacology Bulletin
https://www.readbyqxmd.com/read/28819280/results-of-nopho-all2008-treatment-for-patients-1-45-years-with-acute-lymphoblastic-leukemia
#10
N Toft, H Birgens, J Abrahamsson, L Griškevičius, H Hallböök, M Heyman, T W Klausen, Ó G Jónsson, K Palk, K Pruunsild, P Quist-Paulsen, G Vaitkeviciene, K Vettenranta, A Åsberg, T L Frandsen, H V Marquart, H O Madsen, U Norén-Nyström, K Schmiegelow
Adults with acute lymphoblastic leukemia (ALL) do worse than children. From 7/2008 to 12/2014, Nordic and Baltic centers treated 1509 consecutive patients 1-45 years with Philadelphia chromosome-negative ALL according to the NOPHO ALL2008 without cranial irradiation. 1022 patients were 1-9 years (A), 266 were 10-17 years (B), and 221 were 18-45 years (C). Sixteen patients (three adults) died during induction. All others achieved remission after induction or 1-3 intensive blocks. Subsequently, 45 patients (12 adults) died, 122 patients relapsed (32 adults) with a median time to relapse of 1...
August 18, 2017: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/28816924/treatment-of-premenstrual-breakthrough-of-depression-with-adjunctive-oral-contraceptive-pills-compared-with-placebo
#11
Whitney Peters, Marlene P Freeman, Semmie Kim, Lee S Cohen, Hadine Joffe
PURPOSE/BACKGROUND: Two-thirds of women with depressive disorders report reemergence of depression premenstrually, or premenstrual exacerbation (PME), despite effective treatment of the underlying mood disorder during the remainder of the cycle. There is a paucity of studies that rigorously assess treatments targeting PME. Open-label data suggest that augmentation of antidepressants with the oral contraceptive pill (OCP) drospirenone and ethinyl estradiol (DRSP/EE) improves depressive symptoms that break through treatment premenstrually...
August 15, 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28811854/factors-associated-with-psycho-cognitive-functions-in-patients-with-persistent-pain-after-surgery-for-femoral-neck-fracture
#12
Atsushi Kitayama, Mitsumasa Hida, Hidenobu Takami, Naoki Hirata, Yuko Deguchi, Kazuya Miyaguchi, Masako Nakazono, Rie Nakagawa, Noriyuki Fukumoto, Katsumi Hamaoka
BACKGROUND: The aim of the study was to address issues arising from fracture of the femoral neck in elderly individuals, the prevalence of which continues to increase in Japan. The prevalence is increasing in Japan and there have been many reports on physical functions such as prevention of a fall. However, there have been a few studies that focus on psycho-cognitive functions. We must examine factors in patients with fractured femur necks to develop methods to assist affected patients...
September 2017: Journal of Clinical Medicine Research
https://www.readbyqxmd.com/read/28806745/persistent-mycobacteria-evade-an-antibacterial-program-mediated-by-phagolysosomal-tlr7-8-myd88-in-human-primary-macrophages
#13
Alexandre Gidon, Signe Elisabeth Åsberg, Claire Louet, Liv Ryan, Markus Haug, Trude Helen Flo
Pathogenic mycobacteria reside in macrophages where they avoid lysosomal targeting and degradation through poorly understood mechanisms proposed to involve arrest of phagosomal maturation at an early endosomal stage. A clear understanding of how this relates to host defenses elicited from various intracellular compartments is also missing and can only be studied using techniques allowing single cell and subcellular analyses. Using confocal imaging of human primary macrophages infected with Mycobacterium avium (Mav) we show evidence that Mav phagosomes are not arrested at an early endosomal stage, but mature to a (LAMP1+/LAMP2+/CD63+) late endosomal/phagolysosomal stage where inflammatory signaling and Mav growth restriction is initiated through a mechanism involving Toll-like receptors (TLR) 7 and 8, the adaptor MyD88 and transcription factors NF-κB and IRF-1...
August 2017: PLoS Pathogens
https://www.readbyqxmd.com/read/28796415/white-matter-tract-integrity-is-associated-with-antidepressant-response-to-lurasidone-in-bipolar-depression
#14
Martin J Lan, Harry Rubin-Falcone, Fatima Motiwala, Ying Chen, Jonathan W Stewart, David J Hellerstein, J John Mann, Patrick J McGrath
OBJECTIVES: Patients with bipolar disorder spend the most time in the depressed phase, and that phase is associated with the most morbidity and mortality. Treatment of bipolar depression lacks a test to determine who will respond to treatment. White matter disruptions have been found in bipolar disorder. Previous reports suggest that white matter disruptions may be associated with resistance to antidepressant medication, but this has never been investigated in a prospective study using a Food and Drug Administration (FDA)-approved medication...
August 10, 2017: Bipolar Disorders
https://www.readbyqxmd.com/read/28796022/a-pilot-study-of-the-usefulness-of-a-single-olanzapine-plasma-concentration-as-an-indicator-of-early-drug-effect-in-a-small-sample-of-first-episode-psychosis-patients
#15
Arantzazu Zabala, Mariana Bustillo, Imanol Querejeta, Marta Alonso, Oiane Mentxaka, Ana González-Pinto, Amaia Ugarte, J Javier Meana, Miguel Gutiérrez, Rafael Segarra
PURPOSE/BACKGROUND: Studies analyzing concentration-effect relationships in second-generation antipsychotics have reported contradictory results in chronic schizophrenia. No data are available for the early stages of the disease. The present study aims to evaluate the association between a single olanzapine plasma concentration, clinical response, and severity of adverse effects in first-episode psychosis (FEP); to test the utility of various plasma breakpoints as markers of early response to treatment; and to identify variables affecting olanzapine concentrations...
August 8, 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28790825/rapid-infusion-of-esketamine-for-unipolar-and-bipolar-depression-a-retrospective-chart-review
#16
Fernanda S Correia-Melo, Felipe C Argolo, Lucas Araújo-de-Freitas, Gustavo Carneiro Leal, Flávio Kapczinski, Acioly Luiz Lacerda, Lucas C Quarantini
BACKGROUND: This study evaluated efficacy and safety of intravenous subanesthetic doses of esketamine using an administration time of 10 minutes in patients with treatment-resistant depression and bipolar depression. METHODS: A retrospective chart review was conducted to identify patients who met the inclusion criteria for treatment-resistant depression and bipolar depression according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision criteria, and these patients received rapid infusion of esketamine between June 2012 and December 2015...
2017: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/28790116/targeted-proteomics-identifies-proteomic-signatures-in-liquid-biopsies-of-the-endometrium-to-diagnose-endometrial-cancer-and-assist-in-the-prediction-of-the-optimal-surgical-treatment
#17
Elena Martinez, Antoine Lesur, Laura Devis, Silvia Cabrera, Xavier Matias-Guiu, Marc Hirschfeld, Jasmin Asberger, Jan van Oostrum, María de Los Ángeles Casares de Cal, Antonio Gómez-Tato, Jaume Reventos, Bruno Domon, Eva Colas, Antonio Gil-Moreno
PURPOSE: Endometrial cancer (EC) diagnosis relies on the observation of tumor cells in endometrial biopsies obtained by aspiration i.e., uterine aspirates), but it is associated with 22% undiagnosed patients and up to 50% of incorrectly assigned EC histotype and grade. We aimed to identify biomarker signatures in the fluid fraction of these biopsies to overcome these limitations. EXPERIMENTAL DESIGN: The levels of 52 proteins were measured in the fluid fraction of uterine aspirates from 116 patients by LC-PRM, the latest generation of targeted mass-spectrometry acquisition...
August 8, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28777983/vitamin-d-supplementation-in-bipolar-depression-a-double-blind-placebo-controlled-trial
#18
Wendy K Marsh, Jessica L Penny, Anthony J Rothschild
OBJECTIVE: Bipolar depression is difficult to treat. Vitamin D supplementation is well tolerated and may improve mood via its neurotransmitter synthesis regulation, nerve growth factor enhancement and antioxidant properties. Vitamin D adjunct reduces unipolar depression, but has not been tried in bipolar depression. METHODS: 18-70yos with DSM IV bipolar depression and Vitamin D deficiency (<30 ng/ml) were randomized in a controlled double blind trial of 5000IU Vitamin D3 po qday supplementation versus placebo for twelve weeks...
July 22, 2017: Journal of Psychiatric Research
https://www.readbyqxmd.com/read/28769541/the-psychometric-properties-of-the-quick-inventory-of-depressive-symptomatology-self-report-qids-sr-in-patients-with-hbv-related-liver-disease
#19
Mei Liu, Yuanyuan Wang, Jing Zhao, Sujun Zheng, Gabor S Ungvari, Chee H Ng, Zhong-Ping Duan, Yutao Xiang
BACKGROUND: Comorbid depression in Hepatitis B virus (HBV) is common. Developing accurate and time- efficient tools to measure depressive symptoms in HBV is important for research and clinical practice in China. AIMS: This study tested the psychometric properties of the Chinese version of the 16-item Quick Inventory of Depressive Symptomatology (QIDS-SR) in HBV patients. METHODS: The study recruited 245 depressed patients with HBV and related liver disease...
February 25, 2017: Shanghai Archives of Psychiatry
https://www.readbyqxmd.com/read/28763344/the-impact-of-fatigue-and-energy-on-work-functioning-and-impairment-in-patients-with-major-depressive-disorder-treated-with-desvenlafaxine
#20
David Sarfati, Vanessa C Evans, Edwin M Tam, Cindy Woo, Grant L Iverson, Lakshmi N Yatham, Raymond W Lam
Fatigue and low energy are cardinal symptoms of major depressive disorder (MDD) that have an impact on work functioning. Antidepressants with noradrenergic activity have been hypothesized to improve symptoms of fatigue and low energy. We examined the impact of these symptoms on work functioning in patients with MDD treated with the serotonin and noradrenaline reuptake inhibitor, desvenlafaxine. A secondary analysis was carried out from a study of employed adult outpatients (n=35) with MDD and subjective cognitive complaints treated with desvenlafaxine 50-100 mg/day for 8 weeks...
July 31, 2017: International Clinical Psychopharmacology
keyword
keyword
111401
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"